Diversified science and technology company Danaher (NYSE: DHR) will be reporting earnings this Wednesday before market hours. Here’s what to expect.

Danaher beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $6.05 billion, up 4.4% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly.

Is Danaher a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Danaher’s revenue to grow 4.2% year on year to $6.81 billion, improving from the 2.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.19 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Danaher has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.9% on average.

With Danaher being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, there has been positive investor sentiment in the segment, with share prices up 2.6% on average over the last month. Danaher is up 2.8% during the same time and is heading into earnings with an average analyst price target of $263.05 (compared to the current share price of $238.22).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.